• BAY 57-9352 In recent large clinical studies AIM HIGH and

  2021-09-10

  

  In recent large clinical studies, AIM-HIGH and HPS2-THRIVE, the additional treatment of nicotinic BAY 57-9352 to statin-based LDL-C lowering therapy did not decrease the major vascular events on the patients who had atherosclerotic vascular diseases [43,44]. In the AIM-HIGH study, the secondary anal

• CD binding to gp causes a large scale conformational

  2021-09-10

  

  CD4 binding to gp120 causes a large scale conformational change of gp120 which involves the gp120 core structure and the transitions of inner-domain layers (layer 1, 2 and 3), but also involves the movement of the major loops (V1, V2 and V3) [16], [17], [18], [19]. For instance, the V2-loop joins th

• br The glyoxalase system has not yet

  2021-09-10

  

  The glyoxalase system has not yet been studied in E. histolytica or G. lamblia. Searches in the G. lamblia genome (GiardiaDB.org) revealed two genes encoding hydroxyacylglutathione hydrolases (Morrison et al., 2007), but no glyoxalase I gene was found. The genome of E. histolytica does not have a

• br NMDA receptor LBDs The study of GluA

  2021-09-09

  

  NMDA receptor LBDs The study of GluA2 was later expanded to include NMDA receptors [22]. NMDA receptors are obligate heterotetramers that are composed of two glutamate-binding subunits and two glycine-, or d-serine-, binding subunits. In this study, crystal structures of the NMDA receptor glycine

• Herein in consider of the high

  2021-09-09

  

  Herein, in consider of the high similarity between GR HBP site and AR HBP site, we applied rational drug design strategy to develop AR/GR antagonists based on the chemical structures of antiandrogens and crystal structure of GR. The following bioassay identified Z19 as a dual AR/GR antagonist. Z19 i

• Inhibitors against the proteasome a component

  2021-09-09

  

  Inhibitors against the proteasome, a component of the ubiquitin-proteasome pathway that degrades cellular proteins, provide a new strategy for targeting the 26S proteasome [25]. Proteasome inhibitors can exhibit potent anti-cancer effects against different tumor Tempol and were shown to induce apopt

• In addition to our results Chen et al

  2021-09-09

  

  In addition to our results, Chen et al. showed that administration of the GalR1 antagonist M40 improves cardiac function and attenuates cardiac remodeling in rats with heart failure [26]. These effects might be attributed to M40 suppression of galanin inhibitory effect on the vagal nerve in heart fa

• br The interrelationship between obesity and

  2021-09-09

  

  The interrelationship between obesity and galanin Numerous studies revealed that obesity and galanin may promote each other. On the one hand, galanin may increase the possibility of obesity of subjects via boosting their appetite and food intake. Acute injection with galanin or its agonist, galan

• To date increasing evidence has demonstrated that dysregulat

  2021-09-09

  

  To date, increasing evidence has demonstrated that dysregulated lncRNAs are closely associated with the tumorigenesis and development of HCC via ceRNA modes [29,30]. LncRNAs could bind with special miRNAs and abrogate the inhibitory effect of these miRNAs on their targeted transcripts. For example,

• br Venous thromboembolism VTE is a rare but potentially life

  2021-09-09

  

  Venous thromboembolism (VTE) is a rare but potentially life-threatening complication of total joint arthroplasty (TJA) . With modern chemoprophylaxis, the incidence of VTE after primary total hip (THA) or total knee (TKA) arthroplasty is commonly estimated between 0.5% and 1%, and VTE is now consi

• The EZH overexpression group exhibited upregulated

  2021-09-09

  

  The EZH2 overexpression group exhibited upregulated CEP55 expression but downregulated methylation, suggesting that changes in EZH2 expression in lung adenocarcinoma result in differences of CEP55 methylation and expression. Moreover, according to TCGA database and GSE27262 chip data, CEP55 expressi

• Hyperhomocysteinemia HHcy is a clinical

  2021-09-09

  

  Hyperhomocysteinemia (HHcy) is a clinical condition characterized by increased levels of plasma homocysteine (Hcy) and a well-known risk factor for CVDs. Hcy is a sulfur-containing non-protein amino endothelin receptor antagonist formed during the intracellular conversion of methionine to cysteine.

• Different crystal structures of both HOs were reported and s

  2021-09-09

  

  Different crystal structures of both HOs were reported and showed that the three-dimensional structures of proteins (HO-1: PDB code 1N45, HO-2: PDB code 2QPP) are predominantly in an α-helical conformation, with the heme packed between two helices (distal and proximal), and present a remarkable stru

• Despite these studies little is known

  2021-09-09

  

  Despite these studies, little is known about the regulation of defence genes during AM root colonization. In the present study, we characterized the Ptc52 gene from tomato (named here as SlPtc52), a member of the gene family of non-heme oxygenases, and analysed its molecular characteristics. This ge

• In the present referred patients with hemochromatosis and HF

  2021-09-09

  

  In the present referred patients with hemochromatosis and HFE p.C282Y homozygosity, eight of the ten patients with HCV infection were men. In another US cohort of ten patients with HFE p.C282Y homozygosity, chronic HCV infection, and stage 3 or 4 fibrosis, all were men [30]. In the present post-scre

11158 records 288/744 page Previous Next First page 上5页 286287288289290 下5页 Last page